Cytosorbents (NASDAQ:CTSO) Stock Passes Above Two Hundred Day Moving Average - Here's Why

Cytosorbents Co. (NASDAQ:CTSO - Get Free Report) shares passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $1.05 and traded as high as $1.16. Cytosorbents shares last traded at $1.13, with a volume of 109,611 shares traded.

Analyst Upgrades and Downgrades

CTSO has been the subject of a number of recent research reports. StockNews.com initiated coverage on Cytosorbents in a report on Tuesday. They issued a "hold" rating for the company. D. Boral Capital reissued a "buy" rating and issued a $10.00 target price on shares of Cytosorbents in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Cytosorbents Price Performance

The stock has a market capitalization of $60.15 million, a P/E ratio of -3.06 and a beta of 0.78. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The stock has a 50-day simple moving average of $1.06 and a 200 day simple moving average of $1.05.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its position in shares of Cytosorbents by 7.5% in the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after purchasing an additional 32,415 shares during the last quarter. Skylands Capital LLC boosted its position in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company's stock worth $2,531,000 after purchasing an additional 26,195 shares during the last quarter. Millennium Management LLC bought a new position in shares of Cytosorbents in the 4th quarter worth $30,000. Northern Trust Corp boosted its position in shares of Cytosorbents by 22.3% in the 4th quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock worth $83,000 after purchasing an additional 16,701 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Cytosorbents in the 4th quarter worth $99,000. 32.87% of the stock is currently owned by institutional investors.

Remove Ads

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.